Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dehydrocavidine-containing pharmaceutical composition and preparation method thereof

A technology of dehydrocarvetin and composition, which is applied in the direction of medical preparations containing active ingredients, medical preparations with non-active ingredients, and pharmaceutical formulas, and can solve the problems of slow dissolution rate and collapse of common dehydrocarvetin preparations. Solve problems such as slow solution and failure to reach therapeutic dosage, and achieve the effects of improved dissolution rate, good stability, portability, and good compliance

Active Publication Date: 2015-06-17
GUANGZHOU YIPINHONG PHARMA +4
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to our company's research on this product, it is found that the ordinary preparation of dehydrocarvetin disintegrates slowly, the dissolution rate is slow, and the effective therapeutic dose cannot be achieved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dehydrocavidine-containing pharmaceutical composition and preparation method thereof
  • Dehydrocavidine-containing pharmaceutical composition and preparation method thereof
  • Dehydrocavidine-containing pharmaceutical composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Weigh 5 mg of dehydrocarvetin, 15 mg of precross-linked starch, 10 mg of microcrystalline cellulose, 0.1 mg of sodium lauryl sulfate, 5 mg of crospovidone, 1 mg of croscarmellose sodium, and appropriate amount of sweetness agent, pass through 80 mesh sieve, mix evenly, add dropwise 5% polyvinylpyrrolidone aqueous solution to make soft material, pass through 24 mesh sieve to granulate, dry the granules at 45-80°C, the moisture reaches 0.5-10%, granulate, add Magnesium stearate 0.1 mg, mixed evenly, compressed into tablets.

Embodiment 2

[0051] Weigh 5 mg of dehydrocarvetin, 15 mg of precross-linked starch, 10 mg of microcrystalline cellulose, 0.1 mg of sodium lauryl sulfate, 5 mg of crospovidone, 1 mg of croscarmellose sodium, and appropriate amount of sweetness agent, pass through 80 mesh sieve, mix evenly, add dropwise 5% polyvinylpyrrolidone aqueous solution to make soft material, pass through 24 mesh sieve to granulate, dry the granules at 45-80°C, the moisture reaches 0.5-10%, granulate, add Micropowder silica gel 0.1mg, mixed evenly, compressed into tablets.

Embodiment 3

[0053] Weigh 25 mg of dehydrocarvetin, 15 mg of precrossed starch, 50 mg of lactose, 0.5 mg of sodium lauryl sulfate, 5 mg of crospovidone, 10 mg of croscarmellose sodium, appropriate amount of sweetener, over 80 mesh sieve, mix evenly, dropwise add 5% polyvinylpyrrolidone aqueous solution to make soft material, pass through 24 mesh sieve to granulate, dry the granules at 45-80°C, the moisture reaches 0.5-10%, granulate, add stearic acid Magnesium 1.2mg, mixed evenly, tableted.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a dehydrocavidine-containing pharmaceutical composition. The pharmaceutical composition is in a form of dispersible tablet and comprises 1 to 150 parts by weight of dehydrocavidine and pharmaceutical excipients, wherein the pharmaceutical excipients comprise 10 to 200 parts by weight of disintegrating agent, 0.1 to 10 parts by weight of lubricating agent, 0.1 to 10 parts of flow aid, 0 to 200 parts of filling agent, 0 to 100 parts of adhesive, 0 to 200 parts of swelling agent, 0 to 50 parts of surface active agent, and 0 to 200 parts of corrigent. The dehydrocavidine-containing pharmaceutical composition (dispersible tablet) solves the problem of low dissolution rate of dehydrocavidine, and is high in disintegrative performance and dissolution performance, outstanding in dispersing uniformity, great in taste, convenient to take, high in adaptability, highly obvious in drug utilization rate, fast to act, and obvious in medical function.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition containing dehydrocarvetin and a preparation method thereof. The pharmaceutical composition is a dispersible tablet. Background technique [0002] Hepatitis B virus (Hepatitis B) is an infectious disease caused by DNA hepatotropic virus (HBV) and mainly manifested in liver inflammatory lesions. High-level characteristics are very harmful to human health and are a worldwide public health problem. About 400 million people in the world are chronically infected with HBV, mainly in Asian and African countries. my country is an area with a high incidence of viral hepatitis, mainly HBV infection. Epidemiological data show that there are 120 million HBsAg carriers in my country, and about 30 million chronic hepatitis B patients need treatment, seriously affecting people's life, employment, and even marriage. Although hepatitis B vaccine has been widely used ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4375A61K9/20A61K47/38A61K47/36
Inventor 李捍雄曾永长张莉颜稚宏
Owner GUANGZHOU YIPINHONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com